BFI Co., LLC

SEC source: 0001104659-25-118545 · tm2532723-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 50,128

F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.73 to $41.72.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-118545 · tm2532723-1_4seq1.xml · derivative · entry 6

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 19,961,034

Underlying: Class A Common Stock · 30,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F1 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-118545 · tm2532723-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 53,280

F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.30 to $41.12. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 5 and 6.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-118545 · tm2532723-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 56,800

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-117716 · tm2532519-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 26,800

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.38 to $41.895.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-117716 · tm2532519-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 30,320

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.12 to $43.02. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnote 4.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-116504 · tm2532256-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 33,840

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.79 to $44.37.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-116504 · tm2532256-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 39,120

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.51 to $44.195. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnote 4.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-115420 · tm2531940-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 46,160

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-115420 · tm2531940-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 46,221

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.29 to $42.25. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-113795 · tm2531536-1_4seq1.xml · nonDerivative · entry 4

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 49,680

F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-113795 · tm2531536-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 49,700

F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.27 to $44.26.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-113795 · tm2531536-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 54,960

F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.24 to $44.96. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnote 5.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-113795 · tm2531536-1_4seq1.xml · derivative · entry 6

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 19,991,034

Underlying: Class A Common Stock · 55,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F1 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-113795 · tm2531536-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 60,240

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-111627 · tm2531130-1_4seq1.xml · nonDerivative · entry 4

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 5,240

F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.

F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.86 to $45.465.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-111627 · tm2531130-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 6,894

F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.84 to $44.78.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-111627 · tm2531130-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 14,041

F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.95 to $45.85. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 5 and 6.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-111627 · tm2531130-1_4seq1.xml · derivative · entry 6

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 20,046,034

Underlying: Class A Common Stock · 15,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F1 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-111627 · tm2531130-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 35,577

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-109411 · tm2530686-1_4seq1.xml · nonDerivative · entry 5

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 20,577

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.355 to $46.36.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-109411 · tm2530686-1_4seq1.xml · nonDerivative · entry 4

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 20,897

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.33 to $46.32.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-109411 · tm2530686-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 40,670

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.31 to $45.26.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-109411 · tm2530686-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 54,756

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.31 to $44.28.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-109411 · tm2530686-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 58,880

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.61 to $43.195. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4, 5, 6 and 7.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-107913 · tm2530308-1_4seq1.xml · nonDerivative · entry 5

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 62,400

F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.

F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.67 to $42.14.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-107913 · tm2530308-1_4seq1.xml · nonDerivative · entry 4

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 63,372

F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.

F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.65 to $41.535.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-107913 · tm2530308-1_4seq1.xml · derivative · entry 7

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 20,061,034

Underlying: Class A Common Stock · 25,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F1 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-107913 · tm2530308-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 65,920

F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.555 to $43.705.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-107913 · tm2530308-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 66,444

F3 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI on May 30, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.49 to $43.48. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 5, 6 and 7.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-107913 · tm2530308-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 69,440

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F2 · ownership.nature: The reported securities are directly held by BFI Co., LLC ("BFI"). Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the "Issuer"), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-104520 · tm2529878-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 44,440

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.71 to $41.30.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-104520 · tm2529878-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 47,960

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.33 to $41.94.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-104520 · tm2529878-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 51,480

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.21 to $41.935. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-102227 · tm2529395-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 55,000

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.265 to $42.28.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-102227 · tm2529395-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 58,520

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.46.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-102227 · tm2529395-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 62,040

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $41.555. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-101314 · tm2529035-1_4seq1.xml · derivative · entry 5

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 20,086,034

Underlying: Class A Common Stock · 50,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F5 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-101314 · tm2529035-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 73,899

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · kind: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-101314 · tm2529035-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 23,899

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.59.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-101314 · tm2529035-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 39,974

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.07. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-095629 · tm2527686-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 40,674

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.635. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-092211 · tm2526522-1_4seq1.xml · derivative · entry 4

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 20,136,034

Underlying: Class A Common Stock · 30,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F4 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-092211 · tm2526522-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 61,338

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · kind: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis, at the holder's election, and has no expiration date.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001104659-25-092211 · tm2526522-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 31,338

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.51. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001410578-25-002185 · tm2525853-1_4seq1.xml · nonDerivative · entry 3

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 38,360

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.665 to $41.265.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001410578-25-002185 · tm2525853-1_4seq1.xml · nonDerivative · entry 2

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 41,880

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.23 to $41.39.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001410578-25-002185 · tm2525853-1_4seq1.xml · nonDerivative · entry 1

BENDHEIM JACK · CIK 0001241560 · Director · President and CEO · 10% owner

BFI Co., LLC · CIK 0001601607 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Plan reported

Ownership: Indirect · See

Disclosed balance after: 45,400

F1 · kind: The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC ("BFI") on May 30, 2025.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.81. The Reporting Person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and in footnotes 4 and 5.

F3 · ownership.nature: The reported securities are directly held by BFI. Jack Bendheim, a reporting person, director and officer of the Issuer, exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI. Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001144204-18-049581 · tv502927_4.xml · derivative · entry 3

BFI Co., LLC · CIK 0001601607 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,166,034

Underlying: Class A Common Stock · 30,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017.

F1 · derivative.exercise_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date.

F1 · derivative.expiration_date: Class B Common Stock is convertible into Class A Common Stock at any time on a one-for-one basis and has no expiration date.

SEC source: 0001144204-18-049581 · tv502927_4.xml · nonDerivative · entry 2

BFI Co., LLC · CIK 0001601607 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,480

F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 14, 2017.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.10, inclusive.